Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119

Three-dimensional treatment-planning-based prediction of seed migration to chest after 125I seed brachytherapy for hepatic malignancy

Jiang, H., Li, A., Ke, K., Wu, Z., Huang, J., Huang, N., Shen, Q., Ji, Z., Weizhu, Y., & Lin, J. (2024) · Brachytherapy · doi:10.1016/j.brachy.2024.01.002 · Cited by 2

Oncogene-addicted solid tumors and microbiome—lung cancer as a main character: a narrative review

Guardamagna, M., Meyer, M., Berciano‐Guerrero, M., Mesas-Ruiz, A., Cobo, M., Pérez-Ruiz, E., Cantero, A., Lavado-Valenzuela, R., Barragán, I., Oliver, J., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-216 · Cited by 2

The association between HALP score and survival in patients treated with immune checkpoint inhibitors

Şahin, T. K., Güven, D. C., Durukan, M., Baş, O., Kaygusuz, Y., Arık, Z., Dızdar, Ö., Erman, M., Yalçın, Ş., & Aksoy, S. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2451079 · Cited by 2

Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Kuribayashi, T., Kinoshita, R., Ninomiya, K., Makimoto, G., Kubo, T., Rai, K., Ichihara, E., Hotta, K., Tabata, M., Maeda, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-87232-z · Cited by 2

The immunologic balance: three cases of rituximab-associated melanoma

Davidson, T. M., Markovic, S. N., & Dimou, A. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000799 · Cited by 2

Distinct Mechanisms of Mismatch Repair Deficiency Delineate Two Modes of Response to PD-1 Immunotherapy in Endometrial CarcinomaPreprint

Chow, R. D.-W., Michaels, T., Bellone, S., Hartwich, T. M. P., Bonazzoli, E., Iwasaki, A., Song, E., & Santin, A. D. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4059524 · Cited by 2

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers: The Early Experience of Two Academic CenterPreprint

Mireștean, C. C., Stan, M. C., Schenker, M., Volovat, C. D., Volovăț, S. R., Iancu, D. P. T., Iancu, R. I., & Bădulescu, F. (2023) · Preprints.org · doi:10.20944/preprints202305.0561.v1 · Cited by 2

Immunotherapy: remember the host

Walker, P. R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-743 · Cited by 2

Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy

Yao, Y., Wang, J., Yang, F., & Gao, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.924498 · Cited by 1

Dynamics of the neutrophil‑to‑lymphocyte ratio during lenvatinib treatment for unresectable hepatocellular carcinoma

Kuwano, A., Yada, M., Koga, Y., Tanaka, K., Ohishi, Y., Masumoto, A., & Motomura, K. (2024) · Oncology Letters · doi:10.3892/ol.2024.14442 · Cited by 1

Pre–stereotactic radiosurgery neutrophil-to-lymphocyte ratio predicts post–stereotactic radiosurgery survival of patients with brain metastases concurrently treated with immune checkpoint inhibitors

Yomo, S., Oda, K., & Oguchi, K. (2024) · Journal of neurosurgery · doi:10.3171/2024.5.jns24259 · Cited by 1

The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma

Xie, Y., Sun, H., Shan, L., Ma, X., Sun, Q., & Liu, F. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1454709 · Cited by 1

Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study)

Sato, K., Toh, S., Murakami, T., Nakano, T., Hongo, T., Matsuo, M., Hashimoto, K., Sugasawa, M., Yamazaki, K., Ueki, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1464419 · Cited by 1

Monitoring peripheral blood data supports the prediction of immunotherapy response in advanced non-small cell lung cancer based on real-world data

Ramos-Guerra, A. D., Farina, B., Rubio, J., Vilalta, A., Zugazagoitia, J., Peces‐Barba, G., Seijo, L. M., Paz-Ares, L. G., Bazo, I. G., Gómez, M. D., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03966-9 · Cited by 1

Food Insecurity and Clinical Biomarkers of Inflammation among Cancer Survivors in the All of Us Research Program

Byrne, C. A., Kim, S. J., Kopetsky, G., Karayeva, E., & Oddo, V. M. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-1757 · Cited by 1

Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy

Acosta, R. J., McIntyre, D., Murray, J. C., Anagnostou, V., Brahmer, J. R., Meisel, A., Sezer, A., Gogishvili, M., Melkadze, T., Baramidze, A., et al. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100959 · Cited by 1

Quality-of-life scale machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer

Shen, J., Ma, J., Chen, S., Jin, S., Xu, J., Li, Q., Zhang, C., Tian, X., Chen, X., Wang, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1600265 · Cited by 1

Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study

Murata, D., Azuma, K., Murotani, K., Ito, K., Nomizo, T., Yamada, K., Imabayashi, T., Iwanaga, K., Chibana, K., Ota, T., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108772 · Cited by 1

Clinical and body composition parameters as predictors of response to chemotherapy plus PD-1 inhibitor in gastric cancer

Zhou, C., Sun, Y., Liu, T., van Dijk, D. P. J., Xi, W., Jiang, J., Guo, L., Qi, F., Zhang, X., Jia, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1685592 · Cited by 2

Neutrophil-to-lymphocyte ratio predicts inpatient gout recurrence: a large-scale multicenter retrospective cohort with machine-learning validation

Zhang, H., Liu, J., Lin, R., Xie, D., Lin, W., Zhang, Q., Zhong, F., Chen, S., Huang, Q., Zhang, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688516 · Cited by 1

Neutrophil-to-Lymphocyte Ratio and Mortality in Cardiovascular Disease or Cancer

Morsy, M. I., Friday, J. M., Pell, J. P., Lewsey, J., Mackay, D., Dundas, R., Tran, T., Brown, D., Ho, F. K. W., Hastie, C. E., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102362 · Cited by 3

Peripheral inflammatory indices and outcomes under PD-1/PD-L1–based regimens in HCC: an exploratory single-center retrospective analysis

Qiao, R., Zhu, W., Wang, L., Hei, Y., Wang, X., Yang, R., Kong, S., Qin, H.-Y., & Chen, Y. (2026) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00218-9 · Cited by 1

Peripheral PD-1⁺ T cell signatures predict immunotherapy response and survival in hepatobiliary cancers

Piao, M., Xiao, J., Zhang, N., Li, C., Li, J., Guan, L., Li, S., Zhu, Z., Shi, F., Sun, B., et al. (2026) · Translational research · doi:10.1016/j.trsl.2026.01.004 · Cited by 1

Combined neutrophil-to-lymphocyte ratio and nomogram for predicting progression-free survival in recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors

Xu, Z., Zhang, L., Wang, H., Li, X., Qian, W., Zhao, Z., Yang, K., & Bai, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1811428 · Cited by 1

Comprehensive molecular characterization of cfDNA as predictive and monitoring biomarkers in advanced gastric cancer receiving immunotherapy

Fang, J., Yu, Y., Sun, Y., Ji, M., Jiang, Y., Chen, X., Yan, C., & Jin, G. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013792 · Cited by 1

Spatially-resolved single-cell imaging of melanoma brain metastases identifies localized immune patterns predictive of immune checkpoint blockade response

Voglis, S., Schulz, D., Eling, N., de Souza, N., Regli, L., Neidert, M. C., Czabanka, M., Weller, M., Rhun, É. L., Mihic‐Probst, D., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag128 · Cited by 1

Antibiotic exposure and indication-specific corticosteroid use differentially modulate outcomes of immune checkpoint inhibitor therapy in hepatobiliary malignancies

Yang, J., Wang, W., Jiao, M., Zhang, Z., Lei, S., Lan, N., Chen, M. Y., Wang, Z., Hui, B., Bakhat, T. I. D., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1873839 · Cited by 1

Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer

Solimando, A. G., & Ribatti, D. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_163-1 · Cited by 1

Host-related indexes in head and neck cancer

Valero, C., León, X., & Quer, M. (2023) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000954 · Cited by 1

Case report: Hypereosinophilia in non-small cell lung cancer

Kwon, H., Li, M., Sheldon, J. D., Jones, N., Gallastegui, N., Li, Z., & Owen, D. H. (2024) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2023.100275 · Cited by 1

Tumor mutation load better predicts the prognosis of patients treated with immune checkpoint inhibitors in upper gastrointestinal cancers: A systematic review and meta‐analysis

Ma, C., Teng, Q., Shang, L., Du, F., & Li, L. (2024) · Cancer Reports · doi:10.1002/cnr2.1959 · Cited by 1

Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma

Wang, Y., Song, Y., Wang, R., Wu, Y., Li, M., Xu, K., He, R., Wang, Z., Li, Q., Kong, F., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1265228 · Cited by 2

Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell Carcinoma

Jang, S. Y., Lee, Y., Chun, S. H., Park, J. H., Park, K. U., Chang, H. K., Lee, K., Kim, H. R., Shin, S. H., An, H. J., et al. (2025) · Head & Neck · doi:10.1002/hed.28071 · Cited by 1

Más allá del laboratorio: biomarcadores para transformar la detección y el tratamiento del cáncer con un enfoque social

Martínez, O. Á., Granados, L. I. Q., & Carrillo‐Tapia, E. (2025) · LATAM Revista Latinoamericana de Ciencias Sociales y Humanidades · doi:10.56712/latam.v6i1.3534 · Cited by 1

Prospective Assessment of MR Guided Single-Fraction Stereotactic Ablative Radiation Therapy for Peripheral Lung Metastases: Dosimetric and Clinical Outcomes

Hering, S., Gaus, R., Hofmaier, J., Mansoorian, S., Marschner, S. N., Schmidt-Hegemann, N.-S., Mendes, V. D. S., Tufman, A., Reinmuth, N., Landry, G., et al. (2025) · Practical Radiation Oncology · doi:10.1016/j.prro.2025.05.006 · Cited by 1

Low albumin status accompanies multi-layered immunosuppressive phenotypes in metastatic breast cancer patientsPreprint

Nakamura, Y., Yoda, M., Izumi, Y., Kashima, Y., Takahashi, M., Nakatani, K., Bamba, T., He, C., Konishi, R., Saldajeno, D. P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.05.556440 · Cited by 1

Immunosuppression in the prostate tumor microenvironment is tied to androgen deprivation therapy-resistant club-like cellsPreprint

Kiviaho, A., Eerola, S. K., Kallio, H. M. L., Andersen, M. K., Spotbeen, X., Giesen, A., Parker, C. T. A., Taavitsainen, S., Hantula, O., Marttinen, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.25.586330 · Cited by 1

Prognostic impact of the Controlling Nutritional Status score in patients with esophageal cancer treated with immune checkpoint inhibitorPreprint

Chang, L., Cheng, Q., Ma, Q., He, L., Li, Q., & Tao, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1550376/v1

Neutrophils activated by cancer cells and M2 macrophages promote gastric cancer progression during PD-1 antibody-based immunotherapyPreprint

Zhou, C., Yang, H., Guo, L., Cai, Q., Xi, W., Liu, J., Yuan, F., Zhang, H., Yan, C., Zhu, Z., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1556189/v1

Peripheral blood markers predictive of outcome in Upper gastrointestinal cancers treated with immune checkpoint inhibitorsPreprint

Wang, P., Feng, J. M., Jin, Y., Xu, Z., Cui, X. J., Chen, X., Wei, J., Wang, J., Weng, Y., & Peng, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1562135/v1

Elevated neutrophil-to-lymphocyte ratio induced by tumor and immune cells promotes gastric cancer progression during PD-1 antibody-based treatmentPreprint

Zhou, C., Yang, H., Guo, L., Cai, Q., Xi, W., Liu, J., Yuan, F., Zhang, H., Yan, C., Zhu, Z., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1504776/v1

Immune checkpoint inhibitors in metastatic colorectal cancer therapy (a review)

Сорочан, П. П., Hromakova, I. А., Prokhach, N. E., & Hromakova, I. S. (2022) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2022.3.246760

Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis

Sano, A., Inoue, Y., Kikuchi, H., Fukuchi, K., Funai, K., Imai, A., Matsushita, Y., Tamura, K., Kitagawa, M., & Miyake, H. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00911-z

Bases biologiques de l’immunothérapie anti-cancéreuse

Soumelis, V., Medvedovic, J., & Hoffmann, C. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00097-0

Biomarqueurs en immunothérapie, signatures moléculaires, radiomique : avons-nous avancé ?

Pabst, L., Lopes, S., Kotovskaya, M., Bertrand, B., & Mascaux, C. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00122-7

The product of the PD-L1 expression and neutrophil-to-lymphocyte ratio as a predictor of postoperative recurrence in non-small-cell lung cancerPreprint

Samejima, H., Kojima, K., Fujiwara, A., Tokunaga, T., Okishio, K., & Yoon, H. (2022) · Research Square · doi:10.21203/rs.3.rs-2198117/v1

Peer Review #2 of "Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors (v0.1)"

(2022) · PeerJ · doi:10.7287/peerj.14566v0.1/reviews/2

Peer Review #3 of "Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors (v0.1)"

(2022) · PeerJ · doi:10.7287/peerj.14566v0.1/reviews/3

Changing Face of Inflammatory Activation in Complex Coronary Artery Disease during the COVID-19 Pandemic

Urbanowicz, T. K., Czub, P., Olasińska‐Wiśniewska, A., Michalak, M., Fryska, Z., Zieliński, J., Filipiak, K. J., Wróbel, K., Tykarski, A., & Jemielity, M. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10050199

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresPreprint

Chang, T.-G., Cao, Y., Sfreddo, H. J., Dhruba, S. R., Lee, S., Valero, C., Yoo, S., Chowell, D., Morris, L. G. T., & Ruppin, E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.04.547697

Post-treatment peripheral blood markers as predictive indicators for immune related thyroid dysfunction and outcome in non-small cell lung cancer patients receiving PD-1 inhibitorPreprint

Liu, J., Qin, B., Zhang, X., Cai, L., Bai, N., Tang, Z., Chen, M., & Wang, T. (2023) · Research Square · doi:10.21203/rs.3.rs-3119506/v1

Front-line Chemo-immunotherapy with Nivolumab and Dose-Adjusted (DA) EPOCH in Peripheral T-cell Lymphoma: A Phase I TrialPreprint

Haverkos, B. M., Zain, J. M., Kamdar, M. K., Neuwelt, A. J., Dávila, E., Bradeen, X., Bair, S. M., Jasem, J. A., Smith, C. A., Abbott, D., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3272985/v1

Variation of Peripheral Blood-based Biomarkers for Response of Anti-PD-1 Immunotherapy in Lung CancerPreprint

Yan, F., Wang, X., Chen, D., Ma, Y., & Mo, D. (2023) · Research Square · doi:10.21203/rs.3.rs-3290734/v1

Prospective exploration of a prognostic biomarker of nivolumab for head and neck cancer patients (BIONEXT)Preprint

Sato, K., Toh, S., Murakami, T., Nakano, T., Hongo, T., Matsuo, M., Hashimoto, K., Sugasawa, M., Yamasaki, K., Ueki, Y., et al. (2023) · medRxiv · doi:10.1101/2023.09.05.23295051

Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinomaPreprint

Labidi, S., Meti, N., Barua, R., Li, M., Riromar, J., Jiang, D., Fallah‐Rad, N., Sridhar, S. S., Rincon, S. V. D., Pezo, R. C., et al. (2023) · medRxiv · doi:10.1101/2023.10.03.23296504

Células dendríticas derivadas de monócitos e índices hematológicos em pacientes com glioblastoma submetidos a imunoterapia

Fogolin, C. (2023) · doi:10.11606/d.42.2023.tde-03102023-153945

Crude lymphocyte levels: Can the past accelerate the future in preventive medicine?

Zidar, D. A. (2023) · American Journal of Hematology · doi:10.1002/ajh.27125

Age-Specific Pattern of Nutritional Status by BMI, PG-SGA, and Blood Biomarkers among Cancer PatientsPreprint

Shi, H., Li, S., Li, X.-R., Chen, Y., Liu, C., Zheng, X. M., Liu, T., Xie, H., Lin, S., Zhang, H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3499252/v1

Incorporating the inflammation-related parameters enhances the performance of the nomogram for predicting local control in lung cancer patients treated with stereotactic body radiation therapy

Huang, B.-T., Lin, P.-X., Luo, L., & Wang, Y. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05811-5

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study

Messina, C. G. M., Catalano, M., Roviello, G., Gandini, A., Maruzzo, M., Giorgi, U. D., Pedrazzoli, P., Sbrana, A., Zucali, P. A., Masini, C., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03741-2

Bases biologiques de l’immunothérapie anti-cancéreuse

Mascaux, C., Pabst, L., Soumelis, V., Medvedovic, J., & Hoffmann, C. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00071-5

The efficiency of liposomal paclitaxel versus docetaxel in neoadjuvant chemotherapy with the TPF regimen for locally advanced nasopharyngeal carcinoma: a retrospective study

Yang, Z., Zuo, Q., Liu, R., Wu, H., Chen, J., Li, X., Jia, J., & Xiang, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1465038

Biomarkers in Immune Checkpoint Inhibitor Cancer Treatment

Papageorgiou, A. (2024) · Premier journal of science. · doi:10.70389/pjs.100023

Letter regarding “The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma”

Kosaka, N., & Kataoka, Y. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108020

Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapy

Dai, L., Huang, L., Li, L., Tang, L. M., Yao, J., Shi, Y., & Han, X. (2025) · BMC Cancer · doi:10.1186/s12885-025-14148-2

Durable Response Following the Discontinuation of Immune Checkpoint Inhibitor Therapy in Advanced Non-small Cell Lung Cancer

Nakamura, T., Kawaguchi, Y., Oosawa, J., Imai, K., Aoki, T., Kajiwara, N., & Ikeda, N. (2025) · Cureus · doi:10.7759/cureus.83610

Patient-Derived Three-Dimensional Lung Tumor Models to Evaluate Response to ImmunotherapyPreprint

Goliwas, K. F., Hough, K. P., Sivan, S., Single, S. L., Deshmukh, S. S., Berry, J. L., Khalil, M., Wei, B., Boumber, Y., Athar, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.19.654890

Neutrophil to Lymphocyte Ratio as a Biomarker for the Prediction of Cancer Outcomes and Immune-Related Adverse Events in a CTLA-4-Treated Population

Cunningham, M. M., Romero, R., Álvarez, C., Saxena, S., Schwartz, T. A., & Ishizawar, R. C. (2025) · Cancers · doi:10.3390/cancers17122011

The role of tumor-associated neutrophils in the pathogenesis of recurrent respiratory papillomatosis

Xiao, Y., Niu, Z., Ma, L., & Wang, J. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf055

Predictive Value of the Royal Marsden Hospital Score in Second-line Immunotherapy for Metastatic NSCLC

Aslan, V., Cennet, N. R., Özet, A., Özdemir, N., & Yazıcı, O. (2025) · Journal of Oncological Sciences · doi:10.37047/jos.galenos.2025.2025-5-6

Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial

Park, R., Rind, F., Kristoff, T. J., Li, J., Schell, M. J., Slebos, R. J. C., Thatikonda, S., Chaudhary, R., Poole, M. I., Meshkovska, Y., et al. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001255

Immature Granulocytes and Nivolumab Outcomes in Stage IV Non-Small Cell Lung Cancer: Insights by Tumor Subtype

Ersoy, M. (2025) · Clinical Medicine Insights Oncology · doi:10.1177/11795549251371094

Alteration of Prognostic Factors for Patients with Brain Metastases from Lung Cancer Before and After the Introduction of Immune Checkpoint Inhibitors: A Retrospective Single-Institution Study

Yamamoto, Y., Maetani, T., Narita, H., Terasawa, Y., Kato, N., Akasaki, Y., Murayama, Y., & Tanaka, T. (2025) · Cancers · doi:10.3390/cancers17183067

Immune Checkpoint Inhibitors and Anti-angiogenic Therapy for Cancer

Solimando, A. G., & Ribatti, D. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_163

Predictive and prognostic role of Neutrophil-to-Lymphocyte ratio in patients with advanced thyroid cancer treated with targeted therapy

Diliyaer, T., Ren, Y., Chen, X., Zhu, X., Yilidana, T., Liu, J., Chen, G., & Li, Z. (2025) · Endocrine · doi:10.1007/s12020-025-04449-8

Prognostic nomogram for small-cell lung cancer patients with brain metastasis in China: A population-based real-world analysis

Wang, W., Li, H., Jia, S., Zhang, X., Bai, W., & Li, S. (2025) · Medicine · doi:10.1097/md.0000000000045367

Integration of Delta-Radiomics Features and Inflammatory Biomarkers for Neoadjuvant Chemo-Immunotherapy Efficacy in Locally Advanced Esophageal Squamous Cell Carcinoma

Xu, B., Zhu, J., Fan, T., Lian, J., Ma, J., Zhou, Y., & Lu, H. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s548314

Additional file 1 of Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer

Zhang, C., Huo, Y., Shang, X., Zhang, T., Tang, N., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26074093

Additional file 8 of The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study

Samejima, H., Kojima, K., Fujiwara, A., Tokunaga, T., Okishio, K., & Yoon, H. (2024) · Figshare · doi:10.6084/m9.figshare.26639665

Additional file 1 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer

Li, X., Zhang, Y., Zhu, C., Xu, W., Hu, X., Martínez, D. A. S., Romero, J. L. A., Yan, M., Dai, Y., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.24995511

Additional file 6 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer

Li, X., Zhang, Y., Zhu, C., Xu, W., Hu, X., Martínez, D. A. S., Romero, J. L. A., Yan, M., Dai, Y., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26667598

Additional file 1 of Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis

Liu, T., Li, W., Zhang, Z., Jiang, T., Fei, Y., Huang, J., & Xie, Q. (2022) · Figshare · doi:10.6084/m9.figshare.20508707

Additional file 3 of Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer

Zhang, C., Huo, Y., Shang, X., Zhang, T., Tang, N., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26737332

Additional file 1 of Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Farina, B., Guerra, A. D. R., Bermejo-Peláez, D., Miras, C. P., Peral, A. A., Madueño, G. G., Jaime, J. C., Vilalta, A., Pérez, J. R., Muñoz‐Barrutia, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26572888

Additional file 6 of The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study

Samejima, H., Kojima, K., Fujiwara, A., Tokunaga, T., Okishio, K., & Yoon, H. (2024) · Figshare · doi:10.6084/m9.figshare.26639659

Additional file 2 of Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer

Zhang, C., Huo, Y., Shang, X., Zhang, T., Tang, N., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26074313

Additional file 8 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer

Li, X., Zhang, Y., Zhu, C., Xu, W., Hu, X., Martínez, D. A. S., Romero, J. L. A., Yan, M., Dai, Y., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26667604

Additional file 2 of The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study

Samejima, H., Kojima, K., Fujiwara, A., Tokunaga, T., Okishio, K., & Yoon, H. (2024) · Figshare · doi:10.6084/m9.figshare.24564237

Additional file 7 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer

Li, X., Zhang, Y., Zhu, C., Xu, W., Hu, X., Martínez, D. A. S., Romero, J. L. A., Yan, M., Dai, Y., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26667601

Additional file 4 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer

Li, X., Zhang, Y., Zhu, C., Xu, W., Hu, X., Martínez, D. A. S., Romero, J. L. A., Yan, M., Dai, Y., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26667592

Additional file 1 of Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors

Wang, J., Ma, Y., Lin, H., Wang, J., & Cao, B. (2024) · Figshare · doi:10.6084/m9.figshare.26672616

Additional file 3 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer

Li, X., Zhang, Y., Zhu, C., Xu, W., Hu, X., Martínez, D. A. S., Romero, J. L. A., Yan, M., Dai, Y., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26667589

Additional file 5 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer

Li, X., Zhang, Y., Zhu, C., Xu, W., Hu, X., Martínez, D. A. S., Romero, J. L. A., Yan, M., Dai, Y., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26667595

Additional file 2 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer

Li, X., Zhang, Y., Zhu, C., Xu, W., Hu, X., Martínez, D. A. S., Romero, J. L. A., Yan, M., Dai, Y., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.24995618

Additional file 3 of The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study

Samejima, H., Kojima, K., Fujiwara, A., Tokunaga, T., Okishio, K., & Yoon, H. (2024) · Figshare · doi:10.6084/m9.figshare.26639647

Additional file 1 of The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study

Samejima, H., Kojima, K., Fujiwara, A., Tokunaga, T., Okishio, K., & Yoon, H. (2023) · Figshare · doi:10.6084/m9.figshare.24564146

Additional file 4 of The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study

Samejima, H., Kojima, K., Fujiwara, A., Tokunaga, T., Okishio, K., & Yoon, H. (2024) · Figshare · doi:10.6084/m9.figshare.26639650

Additional file 5 of The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study

Samejima, H., Kojima, K., Fujiwara, A., Tokunaga, T., Okishio, K., & Yoon, H. (2024) · Figshare · doi:10.6084/m9.figshare.26639656

Additional file 7 of The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study

Samejima, H., Kojima, K., Fujiwara, A., Tokunaga, T., Okishio, K., & Yoon, H. (2024) · Figshare · doi:10.6084/m9.figshare.26639662

Additional file 1 of Prognostic value of sarcopenia and inflammatory indices synergy in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy

Xiao, L., Liu, Y., Zhang, X., Nie, X., Bai, H., Lyu, J., & Li, T. (2024) · Figshare · doi:10.6084/m9.figshare.26333220

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictor of Survival and Response to Therapy in Patients Treated with Immune Checkpoint InhibitorsPreprint

Valero, C., Lee, M. A., Hoen, D. R., Weiss, K. L., Kelly, D. J., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3578798

High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).

Florou, V., Park, W., Torres, A. E., Algaze, S. D., Saravia, D., Wilky, B. A., Merchan, J. R., Hosein, P. J., Lockhart, A. C., & Junior, G. L. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e24109

Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis

Sacdalan, D. B., Lucero, J. A., & Sacdalan, D. L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s153290 · Cited by 316

481P The predictive role of neutrophil-to-lymphocyte ratio in patients with solid cancers treated with immune checkpoint inhibitors: A pooled analysis of seven clinical trials of the German AIO study group

Dreikhausen, L., Wiest, I., Keller, R., Marin-Galiano, M., Darr, C., Stein, A., Binder, M., Tintelnot, J., Bozorgmehr, F., Pogorzelski, M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.498

Pre-therapy neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio do not predict survival in patients treated with immune checkpoint inhibitors.

Mann, H., Mushtaq, M. U., Andrade-Gonzalez, X. A., Ahmed, A. T., & Gupta, S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15092 · Cited by 1